113 related articles for article (PubMed ID: 19404848)
1. Immunohistochemical expression of EGFR in colorectal carcinoma correlates with high but not low level gene amplification, as demonstrated by CISH.
Hemmings C; Broomfield A; Bean E; Whitehead M; Yip D
Pathology; 2009; 41(4):356-60. PubMed ID: 19404848
[TBL] [Abstract][Full Text] [Related]
2. Strong nuclear EGFR expression in colorectal carcinomas is associated with cyclin-D1 but not with gene EGFR amplification.
Dekanić A; Dintinjan RD; Budisavljević I; Pećanić S; Butorac MŽ; Jonjić N
Diagn Pathol; 2011 Nov; 6():108. PubMed ID: 22050898
[TBL] [Abstract][Full Text] [Related]
3. Chromogenic in situ hybridization to detect EGFR gene copy number in cell blocks from fine-needle aspirates of non small cell lung carcinomas and lung metastases from colo-rectal cancer.
Simone G; Mangia A; Malfettone A; Rubini V; Siciliano M; Di Benedetto A; Terrenato I; Novelli F; Mottolese M
J Exp Clin Cancer Res; 2010 Sep; 29(1):125. PubMed ID: 20843314
[TBL] [Abstract][Full Text] [Related]
4. Epidermal growth factor receptor overexpression/amplification in adenocarcinomas arising in the gastrointestinal tract.
Rossi E; Villanacci V; Danesino C; Donato F; Nascimbeni R; Bassotti G
Rev Esp Enferm Dig; 2011 Dec; 103(12):632-9. PubMed ID: 22217347
[TBL] [Abstract][Full Text] [Related]
5. Epidermal growth factor receptor expression and gene amplification in colorectal carcinoma: an immunohistochemical and chromogenic in situ hybridization study.
Shia J; Klimstra DS; Li AR; Qin J; Saltz L; Teruya-Feldstein J; Akram M; Chung KY; Yao D; Paty PB; Gerald W; Chen B
Mod Pathol; 2005 Oct; 18(10):1350-6. PubMed ID: 15832190
[TBL] [Abstract][Full Text] [Related]
6. EGFR gene amplification in breast cancer: correlation with epidermal growth factor receptor mRNA and protein expression and HER-2 status and absence of EGFR-activating mutations.
Bhargava R; Gerald WL; Li AR; Pan Q; Lal P; Ladanyi M; Chen B
Mod Pathol; 2005 Aug; 18(8):1027-33. PubMed ID: 15920544
[TBL] [Abstract][Full Text] [Related]
7. Expression of epidermal growth factor receptor in gastric carcinomas.
Takehana T; Kunitomo K; Suzuki S; Kono K; Fujii H; Matsumoto Y; Ooi A
Clin Gastroenterol Hepatol; 2003 Nov; 1(6):438-45. PubMed ID: 15017643
[TBL] [Abstract][Full Text] [Related]
8. Immunohistochemical staining for DNA mismatch repair proteins in intestinal tract carcinoma: how reliable are biopsy samples?
Shia J; Stadler Z; Weiser MR; Rentz M; Gonen M; Tang LH; Vakiani E; Katabi N; Xiong X; Markowitz AJ; Shike M; Guillem J; Klimstra DS
Am J Surg Pathol; 2011 Mar; 35(3):447-54. PubMed ID: 21297438
[TBL] [Abstract][Full Text] [Related]
9. Intratumoral distribution of EGFR-amplified and EGFR-mutated cells in pulmonary adenocarcinoma.
Soma S; Tsuta K; Takano T; Hatanaka Y; Yoshida A; Suzuki K; Asamura H; Tsuda H
Pathol Res Pract; 2014 Mar; 210(3):155-60. PubMed ID: 24355440
[TBL] [Abstract][Full Text] [Related]
10. Protein overexpression and gene amplification of HER-2 and EGFR in colorectal cancers: an immunohistochemical and fluorescent in situ hybridization study.
Ooi A; Takehana T; Li X; Suzuki S; Kunitomo K; Iino H; Fujii H; Takeda Y; Dobashi Y
Mod Pathol; 2004 Aug; 17(8):895-904. PubMed ID: 15143334
[TBL] [Abstract][Full Text] [Related]
11. Molecular subclassification determined by human papillomavirus and epidermal growth factor receptor status is associated with the prognosis of oropharyngeal squamous cell carcinoma.
Nakano T; Yamamoto H; Nakashima T; Nishijima T; Satoh M; Hatanaka Y; Shiratsuchi H; Yasumatsu R; Toh S; Komune S; Oda Y
Hum Pathol; 2016 Apr; 50():51-61. PubMed ID: 26997438
[TBL] [Abstract][Full Text] [Related]
12. Detection of ERBB2 Amplification by Next-Generation Sequencing Predicts HER2 Expression in Colorectal Carcinoma.
Cenaj O; Ligon AH; Hornick JL; Sholl LM
Am J Clin Pathol; 2019 Jun; 152(1):97-108. PubMed ID: 31115453
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of epidermal growth factor receptor (EGFR) by chromogenic in situ hybridization (CISH) and immunohistochemistry (IHC) in archival gliomas using bright-field microscopy.
Marquez A; Wu R; Zhao J; Tao J; Shi Z
Diagn Mol Pathol; 2004 Mar; 13(1):1-8. PubMed ID: 15163002
[TBL] [Abstract][Full Text] [Related]
14. Chromogenic in situ hybridisation testing for HER2 gene amplification in breast cancer produces highly reproducible results concordant with fluorescence in situ hybridisation and immunohistochemistry.
Bilous M; Morey A; Armes J; Cummings M; Francis G
Pathology; 2006 Apr; 38(2):120-4. PubMed ID: 16581651
[TBL] [Abstract][Full Text] [Related]
15. HER2 status in lung adenocarcinoma: a comparison of immunohistochemistry, fluorescence in situ hybridization (FISH), dual-ISH, and gene mutations.
Yoshizawa A; Sumiyoshi S; Sonobe M; Kobayashi M; Uehara T; Fujimoto M; Tsuruyama T; Date H; Haga H
Lung Cancer; 2014 Sep; 85(3):373-8. PubMed ID: 25047676
[TBL] [Abstract][Full Text] [Related]
16. Immunohistochemical staining with EGFR mutation-specific antibodies: high specificity as a diagnostic marker for lung adenocarcinoma.
Wen YH; Brogi E; Hasanovic A; Ladanyi M; Soslow RA; Chitale D; Shia J; Moreira AL
Mod Pathol; 2013 Sep; 26(9):1197-203. PubMed ID: 23599147
[TBL] [Abstract][Full Text] [Related]
17. Determination of Her-2/Neu status in breast carcinoma: comparative analysis of immunohistochemistry and fluorescent in situ hybridization.
Jimenez RE; Wallis T; Tabasczka P; Visscher DW
Mod Pathol; 2000 Jan; 13(1):37-45. PubMed ID: 10658908
[TBL] [Abstract][Full Text] [Related]
18. PGDS, a novel technique combining chromogenic in situ hybridization and immunohistochemistry for the assessment of ErbB2 (HER2/neu) status in breast cancer.
Ni R; Mulligan AM; Have C; O'Malley FP
Appl Immunohistochem Mol Morphol; 2007 Sep; 15(3):316-24. PubMed ID: 17721278
[TBL] [Abstract][Full Text] [Related]
19. Chromogenic
Ali AHM; Yahya AQ; Mohammed HL
Open Access Maced J Med Sci; 2019 Jun; 7(12):1917-1925. PubMed ID: 31406529
[TBL] [Abstract][Full Text] [Related]
20. Analysis of HER-3, insulin growth factor-1, nuclear factor-kB and epidermal growth factor receptor gene copy number in the prediction of clinical outcome for K-RAS wild-type colorectal cancer patients receiving irinotecan-cetuximab.
Scartozzi M; Giampieri R; Maccaroni E; Mandolesi A; Giustini L; Silva R; Zaniboni A; Biscotti T; Biagetti S; Galizia E; Loupakis F; Falcone A; Bearzi I; Cascinu S
Ann Oncol; 2012 Jul; 23(7):1706-12. PubMed ID: 22112971
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
